

September 3, 2026

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
(TSE Growth Code: 4593)

Exhibit at Regenerative Medicine JAPAN 2026 and FIRM Members Presentation

HEALIOS K.K. (“Healios”) will exhibit at BioJapan 2026 / Regenerative Medicine JAPAN 2026 / healthTECH JAPAN 2026, to be held from October 7 to 9, 2026 at PACIFICO Yokohama. During the event, Healios will showcase its business and development pipeline at its exhibition booth, and will also be hosting a presentation exclusive for members of the Forum for Innovative Regenerative Medicine (“FIRM”). Details are as follows.

1. Exhibition Overview

- **Event:** [BioJapan 2026 / Regenerative Medicine JAPAN 2026 / healthTECH JAPAN 2026](#)
- **Date:** October 7 (Wednesday) to 9 (Friday), 2026
- **Venue:** PACIFICO Yokohama
- **Booth:** Regenerative Medicine JAPAN zone, Booth No. R-40

2. FIRM Members Presentation

- **Date/Time:** October 9 (Friday), 2026, 12:45-12:55 (10 minutes)
- **Venue:** Regenerative Medicine Stage (dedicated stage within exhibition hall)
- **Title:** [From Innovation to Manufacturing: Healios’ Regenerative Medicine and CDMO Platform](#)
- **Speaker:** Hironobu Kimura (Head of Kobe Research Institute, Healios)

Through the participation in this event, Healios aims to communicate its ongoing research and development efforts in regenerative medicine, and to create opportunities for dialogue with prospective partner companies and research institutions in Japan and overseas.

About Healios:

HEALIOS K.K. is Japan’s leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. It aims to offer new therapies for patients suffering from diseases without effective treatment options. Healios is a pioneer in the development of regenerative medicines in Japan and owns proprietary, global platforms utilizing both somatic stem cells and iPS cells. In the somatic stem cell field, Healios is developing HLCM051(invimestrocel), a proprietary cell product comprised of multipotent adult progenitor cells (“MAPCs”) derived from the bone marrow of healthy adult donors. HLCM051 has been shown to exhibit powerful anti-inflammatory and immunomodulatory properties with applicability in a range of disease states, has been tested in hundreds of patients in late stage clinical trials, is manufactured consistently at scale in 3D bioreactors, and has demonstrated both safety and suggested efficacy in hundreds of patients across multiple indications. Healios is seeking to advance HLCM051 on a global basis for ARDS, trauma, and ischemic stroke. In the iPSC regenerative medicine field, Healios has developed HLCN061, a next generation NK cell treatment for solid tumors that has been functionally enhanced through gene-modification. These cells have demonstrated robust anti-tumor efficacy in animal models,

benefit from a scalable 3D bioreactor manufacturing process. The development of AKT-01/HLCN061 is currently being led by our development partner, Akatsuki Therapeutics, Inc., in preparation for the initiation of clinical trials. Healios has also established a proprietary, gene-edited “universal donor” induced pluripotent stem cell line to develop next generation regenerative treatments in immuno-oncology, ophthalmology, liver diseases, and other areas of severe unmet medical need. Healios was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 (TSE Growth: 4593).

<https://www.healios.co.jp/en>

Contact:
IR & PR Division
HEALIOS K.K.
E-mail: ir@healios.jp